invivomab anti mouse cd40 (Bio X Cell)

Bio X Cell is a verified supplier

Bio X Cell manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Bio X Cell invivomab anti mouse cd40

(A) Representative images and quantification of CCR7 + DCs (panCK − HLA-DR + LAMP3 + , yellow) near BVs (CD31 + PDPN − , magenta), or LVs (CD31 + PDPN + , cyan) in human tumors (HNSCC, NSCLC, and EC). Scale bar represents 20 μm. Whole-tumor sections were analyzed for EC and NSCLC. Numbers of fields of view (FOVs) analyzed per HNSCC sample are as follows: HNSCC1–04 n = 7; HNSCC1–06 n = 16; HNSCC1–07 n = 11; HNSCC2–01 n = 126; HNSCC2–06 n = 455; HNSCC2–09 n = 180; HNSCC2–11 n = 122; HNSCC2–12 n = 79; HNSCC2–15 n = 205; HNSCC2–26 n = 293; HNSCC2–35 n = 175. One bar = one patient . (B) Representative images and quantification of CCR7 + DCs (FSCN1 + ; yellow) located near BVs (CD31 + LYVE-1 − ; magenta) or LVs (CD31 + LYVE-1 + ; cyan) in mouse tumors (MC38, B16F10, and D4M3.A-OVA). Scale bar represents 10 μm. Whole-tumor sections were analyzed. One bar = one mouse. (C) Frequencies of BV-, LV- and non-vessel-associated CCR7 + DCs in mouse MC38 tumors 3 days post <t>anti-CD40</t> or anti-PD-1 treatment. Whole-tumor sections were analyzed. One bar = one mouse. (D) (Left) Representative images of CCR7 + DCs (FSCN1 + ; yellow) located near BVs (CD31 + LYVE-1 − ; magenta) in MC38 tumors inoculated in Ccr7 ko/wt and Ccr7 ko/ko mice, 3 days post anti-PD-1 treatment. (Right) Distribution of the area of CCR7 + DC surfaces in clusters relative to their distance to closest BVs and plotted as percentage of total CCR7 + DC cluster area. CCR7 + DC surfaces from clusters associated with LVs and those not in clusters were excluded from the analysis. Scale bar represents 20 μm. Whole-tumor sections were analyzed. One dot = average value of all clusters in each genotype ( Ccr7 ko/ko n = 5 mice, 56 clusters; Ccr7 wt /ko n = 6 mice, 28 clusters; and Ccr7 wt /wt n = 3 mice, 19 clusters). Two-way ANOVA with multiple comparisons, mean with SEM; **** p < 0.0001 for comparison at 10 and 20 μm from closest BVs. (E) (Left) Representative images of CCR7 + DCs (FSCN1 + ; yellow) located near BVs (CD31 + LYVE-1 − ; magenta) and Ccl19 ( Ccl19 -eYFP + Tomato + ; white) in Ccl19 -ieYFP reporter mice (left image) or CCL21 (white, right image) in MC38 tumors. (Right) Frequencies of perivascular CCR7 + DC clusters associated with Ccl19 -covered BVs or within CCL21 + areas of the tumors among total perivascular CCR7 + DC clusters. Scale bar represents 20 μm. Whole-tumor sections were analyzed. One dot = one mouse. Unpaired t test, mean with SEM; *** p < 0.001. (F) (Left) Representative images of CCR7 + DCs (FSCN1 + ; yellow) located near BVs (CD31 + LYVE-1 − ; magenta) in MC38 tumors inoculated in Ccl19 wt/wt and Ccl19 ko/ko mice, 2 days post anti-PD-1treatment. (Right) Quantification of BV- or LV-associated CCR7 + DC clusters in MC38 tumors from Ccl19 wt/wt and Ccl19 ko/ko mice. Scale bar represents 20 μm. Whole-tumor sections were analyzed. One dot = one mouse, whiskers represent min to max. Unpaired t test; * p < 0.05. (G) Heatmap depicts log 2 -transformed averaged expression of Ccl19 in indicated immune and non-immune populations in the TME of multiple mouse tumor models (breast, , lung [and GSE201247 ], and pancreatic , ). (H) (Left) Synthetic images of CCR7 + DCs (yellow), blood endothelial cells (BECs; magenta), lymphatic endothelial cells (LECs; cyan), and CCL19 + fibroblasts (green) in one representative NSCLC patient analyzed by spatial transcriptomics. (Right) Box plots depict the enrichment scores of CCL19 + fibroblasts within the neighborhood of BV-associated CCR7 + DCs, in four human NSCLC. Data are shown for both permuted (median enrichment scores from 1,000 permutations) and observed datasets. Scale bar represents 20 μm. Whole-tumor sections were analyzed. One dot = one sample. Paired t test, whiskers represent mean to max; * p < 0.05. (I) Heatmap depicts log 2 -transformed averaged expression of CCL19 in indicated immune and non-immune populations in the TME of multiple human cancer types (HNSCC, n = 40, n = 18 patients; CRC, n = 23, n = 64 patients; ESCC, n = 58 patients ; NSCLC, n = 32, n = 7 patients; BRCA, n = 29 patients ; and PRCA, n = 18 patients ). A cross indicates that the cellular population was not detected. See also – .

Invivomab Anti Mouse Cd40, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 201 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spatial+transcriptomics+st+sequencing/InVivoMAb+anti-mouse+CD40/pmc12882814-135-0-6
Average 96 stars, based on 201 article reviews

invivomab anti mouse cd40 - by Bioz Stars, 2026-09

96/100 stars

Images

1) Product Images from "Positioning and reversible suppression of CCR7 + dendritic cells in perivascular tumor niches shape cancer immunity"

Article Title: Positioning and reversible suppression of CCR7 + dendritic cells in perivascular tumor niches shape cancer immunity

Journal: Immunity

doi: 10.1016/j.immuni.2025.11.020

Figure Legend Snippet: (A) Representative images and quantification of CCR7 + DCs (panCK − HLA-DR + LAMP3 + , yellow) near BVs (CD31 + PDPN − , magenta), or LVs (CD31 + PDPN + , cyan) in human tumors (HNSCC, NSCLC, and EC). Scale bar represents 20 μm. Whole-tumor sections were analyzed for EC and NSCLC. Numbers of fields of view (FOVs) analyzed per HNSCC sample are as follows: HNSCC1–04 n = 7; HNSCC1–06 n = 16; HNSCC1–07 n = 11; HNSCC2–01 n = 126; HNSCC2–06 n = 455; HNSCC2–09 n = 180; HNSCC2–11 n = 122; HNSCC2–12 n = 79; HNSCC2–15 n = 205; HNSCC2–26 n = 293; HNSCC2–35 n = 175. One bar = one patient . (B) Representative images and quantification of CCR7 + DCs (FSCN1 + ; yellow) located near BVs (CD31 + LYVE-1 − ; magenta) or LVs (CD31 + LYVE-1 + ; cyan) in mouse tumors (MC38, B16F10, and D4M3.A-OVA). Scale bar represents 10 μm. Whole-tumor sections were analyzed. One bar = one mouse. (C) Frequencies of BV-, LV- and non-vessel-associated CCR7 + DCs in mouse MC38 tumors 3 days post anti-CD40 or anti-PD-1 treatment. Whole-tumor sections were analyzed. One bar = one mouse. (D) (Left) Representative images of CCR7 + DCs (FSCN1 + ; yellow) located near BVs (CD31 + LYVE-1 − ; magenta) in MC38 tumors inoculated in Ccr7 ko/wt and Ccr7 ko/ko mice, 3 days post anti-PD-1 treatment. (Right) Distribution of the area of CCR7 + DC surfaces in clusters relative to their distance to closest BVs and plotted as percentage of total CCR7 + DC cluster area. CCR7 + DC surfaces from clusters associated with LVs and those not in clusters were excluded from the analysis. Scale bar represents 20 μm. Whole-tumor sections were analyzed. One dot = average value of all clusters in each genotype ( Ccr7 ko/ko n = 5 mice, 56 clusters; Ccr7 wt /ko n = 6 mice, 28 clusters; and Ccr7 wt /wt n = 3 mice, 19 clusters). Two-way ANOVA with multiple comparisons, mean with SEM; **** p < 0.0001 for comparison at 10 and 20 μm from closest BVs. (E) (Left) Representative images of CCR7 + DCs (FSCN1 + ; yellow) located near BVs (CD31 + LYVE-1 − ; magenta) and Ccl19 ( Ccl19 -eYFP + Tomato + ; white) in Ccl19 -ieYFP reporter mice (left image) or CCL21 (white, right image) in MC38 tumors. (Right) Frequencies of perivascular CCR7 + DC clusters associated with Ccl19 -covered BVs or within CCL21 + areas of the tumors among total perivascular CCR7 + DC clusters. Scale bar represents 20 μm. Whole-tumor sections were analyzed. One dot = one mouse. Unpaired t test, mean with SEM; *** p < 0.001. (F) (Left) Representative images of CCR7 + DCs (FSCN1 + ; yellow) located near BVs (CD31 + LYVE-1 − ; magenta) in MC38 tumors inoculated in Ccl19 wt/wt and Ccl19 ko/ko mice, 2 days post anti-PD-1treatment. (Right) Quantification of BV- or LV-associated CCR7 + DC clusters in MC38 tumors from Ccl19 wt/wt and Ccl19 ko/ko mice. Scale bar represents 20 μm. Whole-tumor sections were analyzed. One dot = one mouse, whiskers represent min to max. Unpaired t test; * p < 0.05. (G) Heatmap depicts log 2 -transformed averaged expression of Ccl19 in indicated immune and non-immune populations in the TME of multiple mouse tumor models (breast, , lung [and GSE201247 ], and pancreatic , ). (H) (Left) Synthetic images of CCR7 + DCs (yellow), blood endothelial cells (BECs; magenta), lymphatic endothelial cells (LECs; cyan), and CCL19 + fibroblasts (green) in one representative NSCLC patient analyzed by spatial transcriptomics. (Right) Box plots depict the enrichment scores of CCL19 + fibroblasts within the neighborhood of BV-associated CCR7 + DCs, in four human NSCLC. Data are shown for both permuted (median enrichment scores from 1,000 permutations) and observed datasets. Scale bar represents 20 μm. Whole-tumor sections were analyzed. One dot = one sample. Paired t test, whiskers represent mean to max; * p < 0.05. (I) Heatmap depicts log 2 -transformed averaged expression of CCL19 in indicated immune and non-immune populations in the TME of multiple human cancer types (HNSCC, n = 40, n = 18 patients; CRC, n = 23, n = 64 patients; ESCC, n = 58 patients ; NSCLC, n = 32, n = 7 patients; BRCA, n = 29 patients ; and PRCA, n = 18 patients ). A cross indicates that the cellular population was not detected. See also – .

Techniques Used: Comparison, Transformation Assay, Expressing, Spatial Transcriptomics

(A) (Left) Scheme outlining the experimental setup for bulk RNA-seq analyses of tumor-derived CCR7 + DCs. (Right) GO pathway enrichment analyses performed on differentially expressed genes (DEGs) in CCR7 + DCs in MC38 tumors ( n = 4) from Treg-depleted ( FoxP3 -DTR) compared with Treg-sufficient (WT) mice. Bar plot indicates the −log 10 raw binomial p -values of the top 10 most enriched pathways in CCR7 + DCs. (B) (Left) Experimental setup for ex vivo stimulation of OT-I CD8 + T cells with tumor CCR7 + DCs. (Right) Percentage of OT-I CD8 + T cells that proliferated after 5-day culture with OVA 257–264 peptides-loaded CCR7 + DCs isolated from WT or Treg-depleted tumors. As a control, CCR7 + DCs without OVA 257–264 peptides were used. Two-way ANOVA with multiple comparisons, whiskers represent min to max; ** p < 0.01. (C) (Left) Relative gene expression levels analyzed by bulk RNA-seq. Each dot represents one mouse ( n = 4), whiskers represent mean to max. Unpaired t test with multiple comparisons; * p < 0.05. (Right) Representative histogram of CD40 protein expression and relative mean fluorescence intensity (MFI) measured by FACS and expressed both as normalized values and absolute MFI. Each dot represents one mouse ( n = 18), whiskers represent min to max. Unpaired t test; ** p < 0.01. (D) Analyses of cDCs in tumor-draining lymph nodes. Absolute cell counts (left, n = 10) and MFI of CD40 expression (right, n = 18) measured by FACS in migratory cDCs (CCR7 + CD8α − ) from WT or Treg-depleted mice. Whiskers represent mean to max. (E) (Left) Experimental setup for ex vivo analyses of tumor CCR7 + DCs isolated from anti-PD-1-treated mice that received or not αCD25 NIB mAbs. (Right) CD40 protein expression measured by FACS and expressed both as normalized values and absolute MFI. Each dot represents one mouse ( n = 4 WT and n = 6 FoxP3-DTR), whiskers represent min to max. Unpaired t test; ** p < 0.01. (F) (Left) Overall survival analyses of MC38 tumor-bearing mice treated, or not treated, with αPD-1 and αCD25 NIB mAbs, and in which CD4 + or CD8 + cells were depleted or not ( n = 8 or 9 mice/group). Log-rank Mantel-Cox test; * p < 0.05, *** p < 0.001, and *** p < 0.0001. (Right) Percentage of tumor-free mice on day 60 in the indicated treatment groups. (G) (Left) Experimental setup for ex vivo stimulation of OT-I CD8 + T cells with tumor CCR7 + DCs as in (B). The DCs were obtained from mice receiving anti-PD-1 immunotherapy and that were treated or not with αCD25 NIB mAbs. (Right) Percentage of OT-I CD8 + T cells that proliferated after 5-day culture with OVA 257–264 peptide-loaded CCR7 + DCs. Each dot represents one mouse ( n = 8 and n = 7), whiskers represent min to max. Two-way ANOVA with multiple comparisons; * p < 0.05. (H) (Left) Scheme outlining bone marrow chimeras with inducible Cd40 -deficiency in cDCs and the treatment schedule. (Right) Growth curves of MC38 tumors inoculated in zDC iDTR : Cd40 WT and zDC iDTR : Cd40 KO bone marrow chimeras treated with αPD-1, αCD25 NIB , or αPD-1 + αCD25NIB combination ( n = 8–10 mice/group). Mean with SEM. Two-way ANOVA with multiple comparisons; * p < 0.05 and **** p < 0.0001. See also and .

Figure Legend Snippet: (A) (Left) Scheme outlining the experimental setup for bulk RNA-seq analyses of tumor-derived CCR7 + DCs. (Right) GO pathway enrichment analyses performed on differentially expressed genes (DEGs) in CCR7 + DCs in MC38 tumors ( n = 4) from Treg-depleted ( FoxP3 -DTR) compared with Treg-sufficient (WT) mice. Bar plot indicates the −log 10 raw binomial p -values of the top 10 most enriched pathways in CCR7 + DCs. (B) (Left) Experimental setup for ex vivo stimulation of OT-I CD8 + T cells with tumor CCR7 + DCs. (Right) Percentage of OT-I CD8 + T cells that proliferated after 5-day culture with OVA 257–264 peptides-loaded CCR7 + DCs isolated from WT or Treg-depleted tumors. As a control, CCR7 + DCs without OVA 257–264 peptides were used. Two-way ANOVA with multiple comparisons, whiskers represent min to max; ** p < 0.01. (C) (Left) Relative gene expression levels analyzed by bulk RNA-seq. Each dot represents one mouse ( n = 4), whiskers represent mean to max. Unpaired t test with multiple comparisons; * p < 0.05. (Right) Representative histogram of CD40 protein expression and relative mean fluorescence intensity (MFI) measured by FACS and expressed both as normalized values and absolute MFI. Each dot represents one mouse ( n = 18), whiskers represent min to max. Unpaired t test; ** p < 0.01. (D) Analyses of cDCs in tumor-draining lymph nodes. Absolute cell counts (left, n = 10) and MFI of CD40 expression (right, n = 18) measured by FACS in migratory cDCs (CCR7 + CD8α − ) from WT or Treg-depleted mice. Whiskers represent mean to max. (E) (Left) Experimental setup for ex vivo analyses of tumor CCR7 + DCs isolated from anti-PD-1-treated mice that received or not αCD25 NIB mAbs. (Right) CD40 protein expression measured by FACS and expressed both as normalized values and absolute MFI. Each dot represents one mouse ( n = 4 WT and n = 6 FoxP3-DTR), whiskers represent min to max. Unpaired t test; ** p < 0.01. (F) (Left) Overall survival analyses of MC38 tumor-bearing mice treated, or not treated, with αPD-1 and αCD25 NIB mAbs, and in which CD4 + or CD8 + cells were depleted or not ( n = 8 or 9 mice/group). Log-rank Mantel-Cox test; * p < 0.05, *** p < 0.001, and *** p < 0.0001. (Right) Percentage of tumor-free mice on day 60 in the indicated treatment groups. (G) (Left) Experimental setup for ex vivo stimulation of OT-I CD8 + T cells with tumor CCR7 + DCs as in (B). The DCs were obtained from mice receiving anti-PD-1 immunotherapy and that were treated or not with αCD25 NIB mAbs. (Right) Percentage of OT-I CD8 + T cells that proliferated after 5-day culture with OVA 257–264 peptide-loaded CCR7 + DCs. Each dot represents one mouse ( n = 8 and n = 7), whiskers represent min to max. Two-way ANOVA with multiple comparisons; * p < 0.05. (H) (Left) Scheme outlining bone marrow chimeras with inducible Cd40 -deficiency in cDCs and the treatment schedule. (Right) Growth curves of MC38 tumors inoculated in zDC iDTR : Cd40 WT and zDC iDTR : Cd40 KO bone marrow chimeras treated with αPD-1, αCD25 NIB , or αPD-1 + αCD25NIB combination ( n = 8–10 mice/group). Mean with SEM. Two-way ANOVA with multiple comparisons; * p < 0.05 and **** p < 0.0001. See also and .

Techniques Used: RNA Sequencing, Derivative Assay, Ex Vivo, Isolation, Control, Gene Expression, Expressing, Fluorescence

Injection:

Article Title: CD64 binding potential does not translate into enhanced therapeutic efficacy for anti-IL-23 antibodies under physiologically relevant conditions.
Article Snippet: .. To induce colitis in the Rag2-/- mice, the animals received an intraperitoneal (ip) injection of anti-CD40 (clone FGK4.5; BioXCell, Lebanon, NH, USA) at a dose of 5 mg/kg (0.2 mL) in sterile 1x Dulbecco’s phosphate-buffered saline (DPBS, Ca2+/Mg2+ free) on day 0. .. Anti-IL-23p19-mouse IgG2a WT Fc (AbbVie Bioresearch Center, Worcester, MA, USA; 45 mg/kg, 0.2 mL ip injection), anti-IL-23p19-mouse IgG2a L234A, L235A Fc (AbbVie Bioresearch Center; 45 mg/kg, 0.2 mL ip injection), or 1x DPBS (Ca2+/Mg2+ free; 0.2 mL, vehicle control, ip injection) were administered on day -1 and day 3 (See Table S1 for additional information on anti-IL-23 mAbs).

Sterility:

Saline:

Recombinant:

Article Title: Potentiating dendritic cell immunotherapy by interrupting the Semaphorin 4D-induced immune-suppressive barrier.
Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Pepinimab: monoclonal antiSemaphporin 4D (mab 67) Vaccinex; Rochester, NY https://doi.org/10.1080/13543784. .. 2025.2473055 HER2/ErbB2 (29D8) Rabbit mAb Cell Signaling Cat. 2165S; RRID:AB_10692490 InVivoMAb anti-mouse CD4 (Clone GK1.5) BioXCell Cat. No. BE0003-1; RRID:AB_1107636\1 InVivoMab anti-mouse CD8α (Clone2.43) BioXCell Cat. No. BE0061: RRID:AB_1125541 Rat IgG2b isotype (Clone LTF-2) BioXCell Cat. No. BE0090; RRID:AB_1107780 InVivoPlus anti-mouse CD20 (Clone MB20-11) BioXCell Cat. No. BE0356; RRID:AB_2894775 InVivoPlus anti-mouse CD40 (clone MR-1) BioXCell Cat. No. BE0016-2; RRID:AB_1107647\1 Mouse anti-Cytokeratin 7 Fisher Cat. No. BP1605 Fluorescein (FITC)-AffiniPure Goat AntiMouse IgG (H+L) Fisher Cat. No. 115-095-003; RRID:AB_2338589 Anti-Mouse CD45 BUV395 (Clone 30-F11) BD Biosciences Cat. No. 564279; RRID:AB_2651134 Anti-Mouse CD3 APC (Clone 145-2C11) BD Biosciences Cat. No. 553066; RRID:AB_398529 Anti-Mouse CD8 BV421 (Clone 53–6.7) BD Biosciences Cat. No. 563898; RRID:AB_2738474 Anti-Mouse CD4 BB700 (Clone RM4-5) BD Biosciences Cat. No. 566407; RRID:AB_2744427 Anti-Mouse CD62L BUV737 (Clone MEL-14) BD Biosciences Cat. No. 612833; RRID:AB_2870155 Anti-Mouse CD44 FITC (Clone IM7) BD Biosciences Cat. No. 553133; RRID:AB_2076224 Anti-Mouse CD49b PE (Clone DX5) BioLegend Cat. No. 108908; RRID:AB_313415 Anti-Mouse CD19 PE/Cyanine7 (Clone 6D5) BioLegend Cat. No. 115520; RRID:AB_313655 Anti-Mouse CD45 BUV395 (Clone 30-F11) BD Biosciences Cat. No. 564279; RRID:AB_2651134 Anti-Mouse CD11b PerCP-Cy5.5 (Clone M1/70) BD Biosciences Cat. No. 550993; RRID:AB_394002 Anti-Mouse GR1 APC (Clone RB6-8C5) BD Biosciences Cat. No. 553129; RRID:AB_398532 Anti-Mouse aCD11c PE (Clone N418) BioLegend Cat. No. 117308; RRID:AB_313777 Anti-Mouse CD80 BV421 (Clone 16- 10A1) BioLegend Cat. No. 104725; RRID:AB_10900989 Anti-Mouse F4/80 PE/Cyanine7 (Clone BM8) BioLegend Cat. No. 123114; RRID:AB_893478 Anti-Mouse CD206 BV650 (Clone C086C2) BioLegend Cat. No. 141723; RRID:AB_2562445 Anti-Mouse Tbet AF594 (Clone 4B10) BioLegend Cat. No. 644834; RRID:AB_2728474 Anti-Mouse Interferon gamma BV650 (Clone XMG1.2) BD Biosciences Cat. No. 554412; RRID:AB_395376 Anti-Mouse CD45 FITC (Clone 30-F11) Fisher Cat. No. 11-0451-82; RRID:AB_465050 Anti-Mouse CD11c BV785 (Clone N418) BioLegend Cat. No. 117336; RRID:AB_2565268 Chemicals, peptides, and recombinant proteins HER2/Neu P (5ELAAWCRWGFLLALLPPGIAG) Bachem Holding AG Cat. No. 4108540 (Continued on next page) 16 Cell Reports 45, 117050, March 24, 2026 .. REAGENT or RESOURCE SOURCE IDENTIFIER HER2/Neu P435 (IRGRILHDGAYSLTLQGLGIH) Bachem Holding AG Cat. No. 4108541 HER2/Neu P1209 (SPPHPSPAFSPAFDNLYYWDQ) Bachem Holding AG Cat. No. 4108542 HER3 ECD Class II peptides (p12, p81, p84, p91) Genscript N/A HER3 ICD Class II peptides (p38, p41, p52, p86, p89) Genscript N/A Mouse IL-4 R&D Cat. No. 404-ML-050 Mouse GM-CSF R&D Cat. No. 415-ML-050 ODN1896 Fisher Cat. No. NC9685794 Lipopolysaccharide Signma-Aldrich Cat. No. L4391-1MG RPMI-1640 media Corning Cat. No. 10-040-CM Fetal bovine serum Corning Cat. No. 35-015-CV sodium pyruvate Fisher Scientific Cat. No. MT-25-000-CI L-Glutamine Fisher Cat. No. 25005CI Penicillin/Streptomycin Corning MT-30-002-CI Gentamycin Fisher Cat. No. BW17-519Z Fungizone Life Technologies Cat. No. 17-836E 2-Mercaptoethanol Sigma-Aldrich Cat. No. M3148 nonessential amino acids Corning Cat. No. 25-025-CI Critical commercial assays EasySep CD4 + T Cell Isolation Kit Stemcell Cat. No. 19852 PerkinElmer OPAL 7-Color Automation IHC Kit Leica Biosystems Cat. No. OP-000003 Mouse IFN gamma ELISA Quantikine kit R&D Cat. No. SMIF00 PanCancer IO 360 TM RNASeq Panel NanoString Technologies Cat. No. LBL-10545-01 Metabolic Pathways RNASeq Panel NanoString Technologies Cat. No. LBL-10726-01 Myeloid Innate Immunity RNASeq Panel NanoString Technologies Cat. No. LBL-10398-02 Immunology RNASeq Panel NanoString Technologies Cat. No. LBL-C0268-02 P3 Primary Cell 4D-Nucleofector® X Kit S Lonza Bioscience Cat. No. V4XP-3032 Deposited data NanoString PanCancer Panel Raw Data from this lab This study GEO: GSE302765 NanoString Metabolic Pathways Panel Raw Data from this lab This study GEO: GSE302735 NanoString Myeloid Innate Immunity Panel Raw Data from this lab This study GEO: GSE302763 NanoString Immunology Panel Raw Data from this lab This study GEO: GSE302764 Experimental models: Cell lines Mouse: hHER2 CT26 William E. Carson Lab of Ohio State https://doi.org/10.1158/1078-0432.

Control:

Article Title: Transcriptomic profiling of mouse mammary tumors enables prognostic and predictive biomarker discovery for human breast cancers
Article Snippet: .. The following antibodies and doses were used: anti-PD1 (250 ug, Bio X Cell, BE0146, RRID:AB_10949053), anti-CTLA4 (125 ug, Bio X Cell, BE0164, RRID:AB_10949609), CD40AG (100 ug, Bio X Cell, BE0016-2, RRID:AB_1107647), IgG2a isotype control (125 ug, Bio X Cell, BE0089, RRID:AB_1107769), and IgG2b isotype control (125 ug, Bio X Cell, BE0086, RRID:AB_1107791). ..

Cell Culture:

Article Title: Ectopic B lymphocyte follicles exacerbate ischemic brain damage via MIF-CD74/CXCR4 and interferon signaling
Article Snippet: .. The sorted B cells were cultured in RPMI-1640 cell culture medium added with anti-CD40 antibody (BioXCell, Cat#BE0016-2, 10 μg/mL), anti-IgM antibody (Biolegend, Cat#157102, 10 μg/mL) and R848 (MedChemExpress, Cat#HY-13740, 0.05 μM) for 3 consecutive days. ..

other:

Article Title: Inflammatory arthritis irAE may represent a unique autoimmune disease primarily driven by T cells but likely not autoantibodies.
Article Snippet: Briefly, cells were treated with control, 100 mM 2- deoxy- d- glucose (2- DG), 1 μM oligomycin (Oligo), or a sequential combination of the drugs at the final concentrations for 30 to 45 min; puromycin (10 μg/ml; Invitrogen) was incubated with cells for 20 min. After puromycin treatment, cells were washed in cold PBS and stained with a combination of Fc receptor blockade and cell viability dye and then primary conjugated antibodies against surface markers for 30 min on ice in FACS buffer.

Clinical Proteomics:

Article Title: Triptolide derivative STP1 ameliorates murine systemic lupus erythematosus via targeting Fyn kinase.
Article Snippet: Triptolide has demonstrated potent immunosuppressive properties in multiple autoimmune disorders, but its severe toxicity has greatly hampered clinical application.. Here, we synthesized a triptolide derivative STP1, which exhibits remarkably reduced toxicity compared with triptolide.. Immune dysfunction plays a critical role in systemic lupus erythematosus (SLE), an archetypical and refractory autoimmune disorder with limited therapeutic options and suboptimal outcomes.

Review